XML 53 R42.htm IDEA: XBRL DOCUMENT v3.19.1
Collaborative Research, Development and License Agreements - Additional Information (Detail)
1 Months Ended 3 Months Ended
Feb. 28, 2019
USD ($)
Feb. 28, 2018
USD ($)
Installment
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2018
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Revenue recognized       $ 5,773,000 $ 165,000  
Intangible assets, net       9,445,000   $ 11,717,000
Collaboration Revenue            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Revenue recognized       146,000    
Serum Institute of India Pvt. Ltd. | Collaboration Revenue            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Revenue recognized       100,000 $ 0  
Merck, Sharp & Dohme Corp. | Sublicense Agreement            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Aggregate amount payable to acquire intangible assets   $ 21,000,000.0        
Number of installments | Installment   3        
Payment upon obligation $ 7,000,000.0 $ 7,000,000.0        
Intangible assets, net       $ 9,400,000   $ 11,700,000
Merck, Sharp & Dohme Corp. | Sublicense Agreement | Scenario, Forecast            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Payment upon obligation     $ 7,000,000.0